Xu Liu

State Key Laboratory Of Oncology In South China, Guangdong Key Laboratory Of Nasopharyngeal Carcinoma Diagnosis And Therapy
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.

Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 06, 2026

Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma.

Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma.

Journal: Med (New York, N.Y.)

Published: October 03, 2025

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.

Journal: JAMA

Published: August 21, 2025

Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.

Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.

Journal: Nature

Published: July 30, 2025

Prognostic Value and Therapeutic Implications of MRI-Based Negative Lymph Nodes in Nasopharyngeal Carcinoma.

Prognostic Value and Therapeutic Implications of MRI-Based Negative Lymph Nodes in Nasopharyngeal Carcinoma.

Journal: Cancer medicine

Published: July 26, 2025

Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.

Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.

Journal: Nature cancer

Published: July 23, 2025

Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy.

Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy.

Journal: Nature cancer

Published: June 02, 2025

Association of anti-PD-1 therapy with severe radiation-induced oral mucositis: A retrospective cohort study and validation in the CONTINUUM trial.

Association of anti-PD-1 therapy with severe radiation-induced oral mucositis: A retrospective cohort study and validation in the CONTINUUM trial.

Journal: Med (New York, N.Y.)

Published: February 27, 2025

Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.

Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.

Journal: Oral oncology

Published: September 30, 2024

Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.

Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.

Journal: Signal transduction and targeted therapy

Published: March 19, 2024

Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma.

Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma.

Journal: Cancer cell

Published: August 17, 2023

Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 14, 2023

Showing 1-12 of 68

Last Updated: 09/26/2026